CardiovascularFDA Approved

Eptifibatide (Integrilin)

Intravenous

Overview

A synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri).

Mechanism of Action

Eptifibatide is a potent, reversible glycoprotein IIb/IIIa receptor antagonist that blocks the final common pathway of platelet aggregation by preventing fibrinogen and von Willebrand factor binding to activated platelets..

Research Summary & Key Findings

FDA-approved for acute coronary syndrome and percutaneous coronary intervention. PURSUIT trial showed 1.5% absolute reduction in death or MI at 30 days in ACS patients (NEJM, 1998). ESPRIT trial demonstrated 37% relative reduction in death, MI, or urgent target vessel revascularization at 48 hours in PCI patients. Short half-life (2.5 hours) allows rapid recovery of platelet function after discontinuation.

Clinical Status

FDA Approved

Eptifibatide (Integrilin) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Eptifibatide (Integrilin) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Eptifibatide (Integrilin).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.